Takeda Pharmaceutical Co Ltd (SSE:4502)
円 4300 0 (0%) Market Cap: 6.48 Til Enterprise Value: 10.85 Til PE Ratio: 45.22 PB Ratio: 0.89 GF Score: 76/100

Takeda Pharmaceutical Co Ltd R&D and Plasma-Derived Therapies Day - Tokyo Transcript

Nov 21, 2019 / 02:00AM GMT
Release Date Price: 円4330
Ayako Iwamuro
Takeda Pharmaceutical Company Limited - Manager of IR and Global Finance

[Interpreted] Good morning, ladies and gentlemen. Thank you for joining us today out of your busy schedule. My name is Ayako Iwamuro. I'm from Investor Relations of Global Finance. Very nice to meet you all.

We will have PDT day during the morning. And I'd like to introduce to you the speakers of the PDT day part. We also have a live streaming of today's meetings. So I'd like to introduce to you the speakers of today's morning. First, Julie Kim, President of Plasma-Derived Therapies Business Unit; and Christopher Morabito, Head of R&D Plasma-Derived Therapies.

So now we would like to begin the meeting. But just as a reminder, in today's PDT Day and R&D Day, we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot